<DOC>
	<DOCNO>NCT02446483</DOCNO>
	<brief_summary>This open-label , randomize , single dose , two-sequence , two-period crossover study , separate 7 day washout interval first study drug administration . In study , bioavailability Rabeprazole Idiazole 20 milligram ( mg ) delay release ( DR ) tablets PARIET 20 mg DR tablets single oral dose administration healthy adult fast condition , investigate determine 90 % confidence limit log-transformed ratio ( Test product / Reference product ) bioequivalence parameter . The influence sequence , product period effect test analysis variance ( ANOVA ) . In study total 60 subject plus 1-4 additional subject enrol split two group ( Group A B ) 30 . For subject , total 33 blood draw do volume blood exceed 300 milliliter ( mL ) study . PARIET register trademark EISAI Co. Limited .</brief_summary>
	<brief_title>A Bioequivalence Study Idiazole 20mg DR Tabs PARIETÂ® 20 mg DR Tabs After Single Oral Dose Administration Under Fasting Conditions Healthy Adults</brief_title>
	<detailed_description />
	<mesh_term>Gastrointestinal Diseases</mesh_term>
	<mesh_term>Digestive System Diseases</mesh_term>
	<mesh_term>Rabeprazole</mesh_term>
	<criteria>Healthy male female , age 18 55 year , inclusive . Body weight within 10 percent normal range accord accept normal value body mass index ( BMI ) . Medical demographic without evidence clinically significant deviation normal medical condition . Results clinical laboratory test within normal range deviation consider clinically significant principal investigator . Subject allergy drug investigation . Subjects know allergy product test . Subjects whose value BMI outside accept normal range . Female subject pregnant , nurse take birth control pill . Medical demographic evidence clinically significant deviation normal medical condition . Results laboratory test clinically significant . Acute infection within one week precede first study drug administration . History drug alcohol abuse . Subject agree take prescription nonprescription drug within two week first study drug administration end study . Subject special diet ( example subject vegetarian ) . Subject agree consume beverage foods contain methylxanthenes e.g . caffeine ( coffee , tea , cola , chocolate etc . ) 48 hour prior study administration either study period donate last sample respective period . Subject agree consume beverage foods contain grapefruit 7 day prior first study drug administration end study . Subject history severe disease direct impact study . Participation bioequivalence study clinical study within last 6 week first study drug administration . Subject intend hospitalize within 6 week first study drug administration . Subjects , completion study , would donate 500 mL blood 7 day , 750 mL blood 30 day , 1000 mL 90 day , 1250 mL 120 day , 1500 mL 180 day , 2000 mL 270 day , 2500 mL blood 1 year .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>PARIET 20 mg</keyword>
	<keyword>Rabeprazole</keyword>
	<keyword>Idiazole 20mg</keyword>
	<keyword>bioequivalence</keyword>
</DOC>